What is the generic name for Synagis?
GENERIC NAME: PALIVIZUMAB – INJECTION (pal-ih-VYE-zyou-mab)
What is Synagis vaccine?
Synagis (Palivizumab) Monoclonal Antibody Description for 2022. Synagis (Palivizumab) is a respiratory syncytial virus (RSV) F protein inhibitor monoclonal antibody (mAbs) indicated for the prevention of serious lower respiratory tract disease caused by the Respiratory Syncytial Virus (RSV) in pediatric patients.
Is Synagis a vaccine or medication?
SYNAGIS [si-nah-jis] helps protect babies from RSV through virus-fighting antibodies. SYNAGIS is not a vaccine—it’s an injection given once a month throughout RSV season, which usually starts in the fall and continues into spring.
What is RSV vaccine called?
Just one preventative RSV shot, called Synagis, has been approved. The monthly vaccine from Swedish Orphan Biovitrum can be used in high-risk infants.
What is Synagis made of?
Upon reconstitution, Synagis® (palivizumab) contains the following excipients: 47 mM histidine, 3.0 mM glycine and 5.6% mannitol and the active ingredient, palivizumab, at a concentration of 100 milligrams per mL solution. The reconstituted solution should appear clear or slightly opalescent.
What is the CPT code for Synagis?
90378
Billing and payment for pre-approved Synagis® administration, outside of the specialty pharmacy provider, requires submission of a claim form using the designated CPT 90378 for Synagis®, with a required NDC and entry of billing units incremental to each 50 mg dose administered (i.e. 100mg = 2 billing units).
How is Synagis vaccine administered?
Synagis should be administered in a dose of 15 mg per kg intramuscularly using aseptic technique, preferably in the anterolateral aspect of the thigh. The gluteal muscle should not be used routinely as an injection site because of the risk of damage to the sciatic nerve.
What is the Pfizer RSV vaccine?
The vaccine utilizes a viral fusion protein that RSV uses to attack human cells. The National Institutes of Health found that antibodies specific to the prefusion form of the viral protein were highly effective at blocking virus infection that Pfizer used to inform its investigations of proteins for its vaccine.
Is Synagis a biologic?
Palivizumab, sold under the brand name Synagis, is a monoclonal antibody produced by recombinant DNA technology used to prevent severe disease caused by respiratory syncytial virus (RSV) infections….Palivizumab.
| Monoclonal antibody | |
|---|---|
| Elimination half-life | 18-20 days |
| Identifiers | |
| CAS Number | 188039-54-5 |
| DrugBank | DB00110 |
Who invented Synagis?
ENDPOINTS. AstraZeneca $AZN has divested the US rights to its preventative RSV drug, Synagis, to Swedish Orphan Biovitrum AB (Sobi) for $1.5 billion in cash and stock, as the British drugmaker continues to refine its pipeline and focus on its newer flagship products.
How much does Synagis cost?
under the brand name Synagis, can cost up to $6,000 for five treatments, given to at-risk children in monthly intramuscular injections during RSV season. The company is pushing for wider use, but researchers are divided over its benefits and over when and to whom it should be administered.
When do you administer Synagis?
Dosing Information The recommended dose of Synagis is 15 mg per kg of body weight given monthly by intramuscular injection. The first dose of Synagis should be administered prior to commencement of the RSV season and the remaining doses should be administered monthly throughout the RSV season.